Parkinson's disease remains progressive and, so far, incurable — symptomatic treatment is still built around dopamine. The great hope of the past decade has been disease modification: slowing the underlying process rather than masking symptoms. Two strategies dominate recent trials — clearing pathogenic α-synuclein, and repurposing GLP-1 diabetes drugs for neuroprotection — and the results have been instructive rather than triumphant.
Anti-α-synuclein antibodies: near-misses, not dead ends
Prasinezumab targets aggregated α-synuclein. Its first Phase 2 trial (PASADENA) did not separate from placebo on the primary MDS-UPDRS sum score at 52 weeks. But the story has since become more nuanced: the larger Phase 2b PADOVA trial narrowly missed its primary endpoint (time to confirmed motor progression; hazard ratio 0.84, p=0.0657) while showing a stronger, nominally significant effect in the levodopa-treated majority (HR 0.79) and consistent positive trends across secondary measures. Four-year open-label follow-up from PASADENA suggested sustained slowing of motor progression versus matched natural-history controls. On the strength of these signals, prasinezumab advanced to Phase 3 in 2025 — so this program is best described as an encouraging near-miss, not a failure.
Cinpanemab, a mechanistically similar antibody, tells the opposite story: its Phase 2 SPARK trial showed no difference from placebo and was stopped early for futility. Taken together, the two programs suggest that how and when α-synuclein is targeted — and in which patients — matters enormously.
GLP-1 receptor agonists: a promising signal that Phase 3 did not confirm
Lixisenatide, a GLP-1 receptor agonist repurposed from diabetes, produced the field's most encouraging repurposing signal: in a Phase 2 trial, motor scores held nearly steady while placebo progressed (MDS-UPDRS Part III change −0.04 vs +3.04; difference 3.08 points, P=0.007). Nausea (46%) and vomiting (13%) were common.
The essential update, however, is that the larger and longer Phase 3 Exenatide-PD3 trial (a different GLP-1 agonist) found no slowing of Parkinson's progression over 96 weeks. As of 2025, no GLP-1 therapy has demonstrated disease modification in a Phase 3 trial, and the conflicting results have prompted questions about brain penetration and patient selection. Trials of other GLP-1 agents (including semaglutide) continue, so the pathway is not closed — but the early enthusiasm now carries an important caveat.
| Drug | Mechanism | Result | Status |
|---|---|---|---|
| Prasinezumab | Anti-α-synuclein | PASADENA missed primary; PADOVA narrow miss with levodopa-subgroup signal | Advancing to Phase 3 (2025) |
| Cinpanemab | Anti-α-synuclein | No effect; stopped for futility | Discontinued |
| Lixisenatide | GLP-1 agonist | Positive Phase 2 (MDS-UPDRS III, P=0.007) | Needs confirmation |
| Exenatide | GLP-1 agonist | Negative Phase 3 (no slowing) | Not disease-modifying |
The near-term lesson is sobering but useful: several plausible disease-modifying strategies have produced signals without definitive Phase 3 wins. Future progress will likely hinge on earlier intervention, better brain delivery, and biomarker-based selection of the patients most likely to respond.
Further reading: PASADENA (Pagano et al., NEJM 2022) and PADOVA (Roche/Prothena, 2024–2025); Lixisenatide (Meissner et al., NEJM 2024); Exenatide-PD3 (Vijiaratnam et al., Lancet 2025); Cinpanemab/SPARK (Lang et al., NEJM 2022).